Bevacizumab, dacarbazine and interferon alfa-2a combination as a first-line therapy in patients with locally advancing or metastatic melanoma

Trial Profile

Bevacizumab, dacarbazine and interferon alfa-2a combination as a first-line therapy in patients with locally advancing or metastatic melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Bevacizumab; Dacarbazine; Interferon alpha-2a
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2009 Planned number of patients changed from 40 to 27 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual end date (April 2009) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top